Beyond therapeutics, GPC3 is also being actively pursued as a diagnostic imaging target; for example, 89Zr-labeled anti-GPC3 antibodies have enabled high-contrast PET imaging of HCC xenografts, highlighting the potential of GPC3-targeted molecular imaging to improve early tumor detection and treatment monitoring [8,9]. Here, GPC3 is linked to neoplasm.